[go: up one dir, main page]

WO2003075824A3 - Process of manufacturing pharmaceutical composition useful for management of tuberculosis - Google Patents

Process of manufacturing pharmaceutical composition useful for management of tuberculosis Download PDF

Info

Publication number
WO2003075824A3
WO2003075824A3 PCT/IB2003/000801 IB0300801W WO03075824A3 WO 2003075824 A3 WO2003075824 A3 WO 2003075824A3 IB 0300801 W IB0300801 W IB 0300801W WO 03075824 A3 WO03075824 A3 WO 03075824A3
Authority
WO
WIPO (PCT)
Prior art keywords
tuberculosis
management
pharmaceutical composition
composition useful
manufacturing pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/000801
Other languages
French (fr)
Other versions
WO2003075824A2 (en
Inventor
Bakulesh Mafatlal Khamar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2003209533A priority Critical patent/AU2003209533A1/en
Priority to JP2003574100A priority patent/JP2005519941A/en
Priority to KR10-2003-7015465A priority patent/KR20050008453A/en
Priority to BR0303367-8A priority patent/BR0303367A/en
Publication of WO2003075824A2 publication Critical patent/WO2003075824A2/en
Publication of WO2003075824A3 publication Critical patent/WO2003075824A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the treatment of tuberculosis.
PCT/IB2003/000801 2002-03-08 2003-03-04 Process of manufacturing pharmaceutical composition useful for management of tuberculosis Ceased WO2003075824A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003209533A AU2003209533A1 (en) 2002-03-08 2003-03-04 Process of manufacturing pharmaceutical composition useful for management of tuberculosis
JP2003574100A JP2005519941A (en) 2002-03-08 2003-03-04 Method for producing a pharmaceutical composition useful for the management of tuberculosis
KR10-2003-7015465A KR20050008453A (en) 2002-03-08 2003-03-04 Process of manufacturing pharmaceutical composition useful for management of tuberculosis
BR0303367-8A BR0303367A (en) 2002-03-08 2003-03-04 Mycobacterium w cells, pharmaceutically acceptable carrier, preservative, mycobacterium w disruption, solvent extraction, enzymes used for enzymatic extraction of mycobacterium w cells, adjuvant, pharmaceutical composition, surfactant, and surfactant concentration of the process of making a composition pharmaceutical for the administration of tuberculosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN236/MUM/2002 2002-03-08
IN236MU2002 2002-03-08

Publications (2)

Publication Number Publication Date
WO2003075824A2 WO2003075824A2 (en) 2003-09-18
WO2003075824A3 true WO2003075824A3 (en) 2003-12-24

Family

ID=27799868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000801 Ceased WO2003075824A2 (en) 2002-03-08 2003-03-04 Process of manufacturing pharmaceutical composition useful for management of tuberculosis

Country Status (5)

Country Link
JP (1) JP2005519941A (en)
KR (1) KR20050008453A (en)
AU (1) AU2003209533A1 (en)
BR (1) BR0303367A (en)
WO (1) WO2003075824A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636391B2 (en) 2007-04-12 2017-05-02 Mico Bio, Inc. Tuberculosis vaccine and method of using same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
WO2003063897A1 (en) * 2002-01-29 2003-08-07 Modi, Rajiv, Indravadan Method of providing prophylaxis for tuberculosis in hiv positive individuals
CA2681420A1 (en) * 2007-03-20 2008-09-25 Cadila Pharmaceuticals Limited P38 inhibitors
WO2009001204A2 (en) * 2007-06-28 2008-12-31 Cadila Pharmaceuticals Ltd. Mitogen activated protein kinase modulator
FR2979826B1 (en) * 2011-09-08 2013-12-27 Univ Bordeaux Segalen ANTI-INFLAMMATORY COMPOSITION
KR101696514B1 (en) * 2014-08-18 2017-01-24 서울대학교산학협력단 Temperature Sensitive Mycobacterial strain and its use as vaccine against mycobacterial infection disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567585A (en) * 1963-07-12 1971-03-02 Ciba Geigy Corp Process for obtaining bcg-cultures
JPS4843842B1 (en) * 1970-07-17 1973-12-21

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567585A (en) * 1963-07-12 1971-03-02 Ciba Geigy Corp Process for obtaining bcg-cultures
JPS4843842B1 (en) * 1970-07-17 1973-12-21

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 197401, Derwent World Patents Index; AN 1974-01695V/01 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636391B2 (en) 2007-04-12 2017-05-02 Mico Bio, Inc. Tuberculosis vaccine and method of using same

Also Published As

Publication number Publication date
AU2003209533A8 (en) 2003-09-22
KR20050008453A (en) 2005-01-21
BR0303367A (en) 2004-07-20
AU2003209533A1 (en) 2003-09-22
WO2003075824A2 (en) 2003-09-18
JP2005519941A (en) 2005-07-07

Similar Documents

Publication Publication Date Title
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
AU2002302919A1 (en) Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
WO2004037222A3 (en) Sustained-release tramadol formulations with 24-hour efficacy
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
AU2001295939A1 (en) Process for preparation of polyisocyanate composition
AU2003265589A1 (en) Process for the preparation of 1,1,1,2,2-pentafluoroethane
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
CA2484494A1 (en) High dose ibandronate formulation
AU2003230189A1 (en) Oral controlled release pharmaceutical composition containing metaxalone as active agent
WO2003075824A3 (en) Process of manufacturing pharmaceutical composition useful for management of tuberculosis
AU2003231920A1 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
PL371310A1 (en) Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase
AU2002338201A1 (en) Anthelmintic composition
AU2002325614A1 (en) Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances
AU2003246840A1 (en) Anti-hiv composition, production method thereof and medicament
AU2003219507A1 (en) Process for the preparation of highly pure torsemide
AU2003208510A1 (en) Process for manufacturing pharmaceutical composition comprises of mycobacterium w in the treatment of asthma(obstructive lung disease)
WO2002064124A3 (en) Medicament formulation containing a muscarinic agonist
AU2003223098A1 (en) Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
WO2003075825A3 (en) The method of treating tuberculosis
AU2003224495A1 (en) Process for the preparation of enantiomerically enriched compounds
AU2003269482A1 (en) Process for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde
AU2002240835A1 (en) Process for the manufacture of solid formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020037015465

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003574100

Country of ref document: JP

122 Ep: pct application non-entry in european phase